Table 1.

Clinical trials targeting adenosine signaling in lung diseases.

Drug(Company)	Target	Status	Target disease	Clinical trial gov identifier	References
GW328267X	A2A adenosine receptor agonist	Completed Phase 1	Acute lung injury	NCT01640990
PBF-680	A1 adenosine receptor antagonist	Completed Phase 2	Asthma	NCT01939587
PBF-680	A1 adenosine receptor antagonist	Recruiting Phase 2	Asthma	NCT02635945
PBF-680	A1 adenosine receptor antagonist	Completed Phase 1	Asthma	NCT01845181
PBF-680	A1 adenosine receptor antagonist	Completed Phase 1	Asthma	NCT02208973
PBF-680	A1 adenosine receptor antagonist	Recruiting Phase 2	Persistent, mild-to-moderate atopic asthma	NCT03774290
Regadenoson	A2A adenosine receptor agonist	Completed Phase4	As stress agents for myocardial perfusion imaging in asthma or COPD patients	NCT00862641	(179)
Dipyridamole	Equilibrative nucleoside transporter inhibitor	Recruiting Phase 2	COVID-19; SARS-CoV-2 infection	NCT04391179
Dipyridamole	Equilibrative nucleoside transporter inhibitor	Recruiting Phase 2	COVID-19 pneumonia; Vascular complications	NCT04424901
Vadadustat	Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor	Recruiting Phase 2	Acute respiratory distress syndrome; coronavirus infection	NCT04478071